Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

EvCe Jun. 17 at 1:20 PM

$CABA this week $2.5

0 · Reply

WastedTrader Jun. 16 at 8:24 PM

$CABA

0 · Reply

Moonman321 Jun. 16 at 7:54 PM

$CABA medium price target $25 Don’t say those famous words I wish I would’ve bought more

0 · Reply

Moonman321 Jun. 16 at 7:50 PM

$CABA locked and ready 💪🏻

0 · Reply

BullAlwaysTop Jun. 16 at 7:26 PM

$CABA guys what about the results on 25 june? Its droping?

1 · Reply

EvCe Jun. 16 at 5:19 PM

$SBET hold n wait $CABA adding more @ 1.92

0 · Reply

Enea1977 Jun. 16 at 3:16 PM

$CABA can someone explaine me why with a green market like today we are so down? Come on buy the dip...

1 · Reply

Moonman321 Jun. 16 at 2:01 PM

$CABA added nicely

0 · Reply

Moonman321 Jun. 16 at 4:59 AM

$CABA grabbing a starter position of 20,000 shares Good news from the Fed this week incoming The fed will be cutting Small cap heaven This is going to re-rate 2025 the year of the squeeze 🐻 🔥

0 · Reply

Winning_calls Jun. 16 at 3:17 AM

$CABA pick me up @ $2

0 · Reply

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 5 days ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 6 days ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 6 days ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 19 days ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 4 weeks ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 2 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 3 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 3 months ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 4 months ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 4 months ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 4 months ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 4 months ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 5 months ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 8 months ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 9 months ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 28, 2024, 8:00 AM EDT - 10 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 8, 2024, 7:00 AM EDT - 11 months ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 1 year ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 1 year ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 1 year ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 1 year ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 1 year ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 1 year ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 1 year ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 1 year ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 19, 2023, 4:56 AM EDT - 1 year ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

May 31, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 22, 2023, 4:30 PM EDT - 2 years ago

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 21, 2023, 8:20 AM EDT - 2 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CYH EXAS MRNA NVAX ORGO PFE RARE

May 17, 2023, 10:16 PM EDT - 2 years ago

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 17, 2023, 4:01 PM EDT - 2 years ago

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 16, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 11, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 4:35 PM EDT - 2 years ago

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

Apr 27, 2023, 4:49 PM EDT - 2 years ago

Cabaletta Bio: Speculative Biotech With Opportunity

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

EvCe Jun. 17 at 1:20 PM

$CABA this week $2.5

0 · Reply

WastedTrader Jun. 16 at 8:24 PM

$CABA

0 · Reply

Moonman321 Jun. 16 at 7:54 PM

$CABA medium price target $25 Don’t say those famous words I wish I would’ve bought more

0 · Reply

Moonman321 Jun. 16 at 7:50 PM

$CABA locked and ready 💪🏻

0 · Reply

BullAlwaysTop Jun. 16 at 7:26 PM

$CABA guys what about the results on 25 june? Its droping?

1 · Reply

EvCe Jun. 16 at 5:19 PM

$SBET hold n wait $CABA adding more @ 1.92

0 · Reply

Enea1977 Jun. 16 at 3:16 PM

$CABA can someone explaine me why with a green market like today we are so down? Come on buy the dip...

1 · Reply

Moonman321 Jun. 16 at 2:01 PM

$CABA added nicely

0 · Reply

Moonman321 Jun. 16 at 4:59 AM

$CABA grabbing a starter position of 20,000 shares Good news from the Fed this week incoming The fed will be cutting Small cap heaven This is going to re-rate 2025 the year of the squeeze 🐻 🔥

0 · Reply

Winning_calls Jun. 16 at 3:17 AM

$CABA pick me up @ $2

0 · Reply

Himtan1 Jun. 14 at 1:43 AM

$CABA Added more yesterday.

0 · Reply

Daniel_Ocean Jun. 14 at 12:53 AM

$CABA

0 · Reply

Reallybigbags Jun. 14 at 12:49 AM

$CABA started a position today 10k shares

0 · Reply

dantes13 Jun. 13 at 9:21 PM

$CABA 🍸❓️🤔💥💥🔥🔥🚀🚀🚀

0 · Reply

EvCe Jun. 13 at 8:40 PM

$CABA I’m in from $1,74

0 · Reply

Hbbu3 Jun. 13 at 8:34 PM

$CABA 13.43% short interest

0 · Reply

RunnerSignals Jun. 13 at 8:23 PM

Solar Squad Heats Up! $RUN and $SEDG lit up the boards $CABA and $ETNB chased the rally and $ARRY slipped into the party late. Who's got the stamina for Monday?

0 · Reply

Enea1977 Jun. 13 at 8:02 PM

$CABA Looks like the 10k shares loaded at 1,67 yesterday have been a bargain so far...always buy the dip great future ahead...

0 · Reply

KNCourt24 Jun. 13 at 7:57 PM

$CABA 👀🚀

0 · Reply

WastedTrader Jun. 13 at 7:52 PM

$CABA 💪💪💪

0 · Reply

KNCourt24 Jun. 13 at 7:02 PM

$CISO $CABA my two long holds both gems with huge potential🚀

1 · Reply

KNCourt24 Jun. 13 at 3:45 PM

$CABA Looks beautiful on a red day. Next week back over 2.30

0 · Reply

Market Cap	100.98M
Revenue (ttm)	0.00
Net Income (ttm)	-115.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,904,800
Avg Vol	1,990,104
Day's Range	N/A - N/A
Shares Out	50.74M
Stochastic %K	36%
Beta	2.81
Analysts	Strong Sell
Price Target	$15.89